@article {17379,
	title = {High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece},
	journal = {Int J STD AIDSInt J STD AIDSInt J STD AIDS},
	volume = {25},
	number = {12},
	year = {2014},
	note = {Panagopoulos, PParaskevis, DKatsarolis, ISypsa, VDetsika, MProtopapas, KAntoniadou, APapadopoulos, APetrikkos, GHatzakis, AengEngland2014/02/12 06:00Int J STD AIDS. 2014 Oct;25(12):860-5. doi: 10.1177/0956462414523259. Epub 2014 Feb 10.},
	month = {Oct},
	pages = {860-5},
	abstract = {Hyperbilirubinaemia with or without jaundice is one of the side effects of atazanavir boosted with low-dose ritonavir (ATV/rit) related to the drug plasma levels, as a result of its metabolism by UGT1A1 - uridine diphosphate-glucuronosyl transferase. Genotyping for UGT1A1*28 before initiation of antiretroviral therapy containing atazanavir may aid in identifying individuals at risk of hyperbilirubinaemia. Our objective was to estimate the prevalence of the UGTA1A1*28 polymorphism in HIV-infected individuals in Greece and to determine its potential association with hyperbilirubinaemia in patients receiving ATV/rit. The prevalence of the UGTA1A1*28 variant was estimated in 79 HIV-infected patients prior to the administration of the first-line treatment. The UGTA1A1*28 variant was detected in 46 out of 79 individuals (58.2\%). Antiretroviral therapy was administered to 64/79 patients (81\%). Among them, 26/64 (40.6\%) received ATV/rit. Of the ATV/rit-treated patients, 14 were found to be carriers of the UGT1A1*28 variant (54\%), and maximum serum bilirubin levels were significantly higher in the carrier population (4.71 vs. 2.69 mg/dL, p = 0.026). In 50\% of the population, maximum levels were recorded in the first month of follow-up. Although carriage of UGT1A1 is linked with the development of hyperbilirubinaemia, the implementation of a pharmacogenomic approach in clinical practice cannot yet be recommended as a standard of care.},
	keywords = {*Polymorphism, Genetic, Adult, Aged, Anti-HIV Agents/*administration \& dosage/adverse effects, Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Bilirubin/metabolism, Cross-Sectional Studies, Glucuronosyltransferase/*genetics, Greece/epidemiology, HIV Infections/*drug therapy/epidemiology, HIV Protease Inhibitors/*administration \& dosage/adverse effects, Humans, Hyperbilirubinemia/chemically induced/enzymology/*genetics, Middle Aged, Oligopeptides/*administration \& dosage/adverse effects, Pharmacogenetics, Prevalence, Pyridines/*administration \& dosage/adverse effects, Ritonavir/administration \& dosage},
	isbn = {1758-1052 (Electronic)0956-4624 (Linking)},
	author = {Panagopoulos, P and Paraskevis, D and Katsarolis, I and Sypsa, V and Detsika, M and Protopapas, K and Antoniadou, A and Papadopoulos, A. and Petrikkos, G and Hatzakis, A}
}
